Medivir has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering the combination of its peptide prodrug fostrox and lenvatinib for treating liver cancers. This approval strengthens the company's intellectual property position in the US market, extending potential market exclusivity for this combination therapy until at least 2041.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.